慢性可诱导性荨麻疹的治疗进展

doi:10.35541/cjd.20210677

Abstract

Abstract: 【Abstract】 At present, the pathogenesis of chronic inducible urticaria （CIndU） is not completely clear, and it is often difficult to achieve satisfactory symptom control only by avoiding triggers. In recent years, some progress has been made in the treatment of CIndU in China and other countries, such as traditional antihistamines, non-antihistamines, biological agents, small-molecule targeted drugs and other drug treatments, as well as physical therapies such as trigger-point desensitization therapy. This review comprehensively and systematically outlines and summarizes relevant progress.

Key words: Urticaria, Therapy, Histamine antagonists, Biological agents, Chronic inducible urticaria, Physical urticaria

Chen Qiquan, Song Zhiqiang. Treatment of chronic inducible urticaria[J]. Chinese Journal of Dermatology, 2021, 54(12): 1110-1113.doi:10.35541/cjd.20210677

References ［37］

［1］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［2］	Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1119⁃1130. doi: 10.1016/j.jaip.2018.03.007.
［3］	Maurer M, Hawro T, Krause K, et al. Diagnosis and treatment of chronic inducible urticaria［J］. Allergy, 2019,74（12）:2550⁃2553. doi: 10.1111/all.13878.
［4］	Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study［J］. J Dermatol Sci, 2017,87（1）:60⁃69. doi: 10. 1016/j.jdermsci.2017.02.283.
［5］	Pereira A, Motta AA, Kalil J, et al. Chronic inducible urticaria: confirmation through challenge tests and response to treatment［J］. Einstein （Sao Paulo）, 2020,18:eAO5175. doi: 10.31744/einstein_journal/2020ao5175.
［6］	Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management［J］. Clin Auton Res, 2018,28（1）:103⁃113. doi: 10. 1007/s10286⁃017⁃0418⁃6.
［7］	Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ what we know and what we do not know［J］. Allergy, 2021,76（4）:1077⁃1094. doi: 10.1111/all.14674.
［8］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd. 14543.
［9］	Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options［J］. J Allergy Clin Immunol, 2018,141（5）:1726⁃1734. doi: 10.1016/j.jaci.2018. 01.031.
［10］	Cassano N, Mastrandrea V, Vestita M, et al. An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatment［J］. Dermatol Ther, 2009,22 Suppl 1:S22⁃S26. doi: 10.1111/j.1529⁃8019.2009.01268.x.
［11］	Morgado⁃Carrasco D, Fustà⁃Novell X, Podlipnik S, et al. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature［J］. Photodermatol Photoimmunol Photomed, 2018,34（3）:194⁃199. doi: 10.1111/phpp.12370.
［12］	Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options［J］. J Allergy Clin Immunol Pract, 2020,8（9）:3141⁃3161. doi: 10. 1016/j.jaip.2020.05.016.
［13］	Wang F, Zhao YK, Luo ZY, et al. Aquagenic cutaneous disorders［J］. J Dtsch Dermatol Ges, 2017,15（6）:602⁃608. doi: 10.1111/ddg.13234.
［14］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA（2） LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884.
［15］	Kozaru T, Fukunaga A, Taguchi K, et al. Rapid desensitization with autologous sweat in cholinergic urticaria［J］. Allergol Int, 2011,60（3）:277⁃281. doi: 10.2332/allergolint.10⁃OA⁃0269.
［16］	Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction［J］. Dermatology, 2012,224（2）:101⁃105. doi: 10.1159/000336572.
［17］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd. 14543.
［18］	Aguilera P. Inducing light tolerance with narrowband UV⁃B therapy in solar urticaria［J］. Actas Dermosifiliogr （Engl Ed）, 2018,109（10）:853. doi: 10.1016/j.ad.2018.06.009.
［19］	Takahagi S, Tanaka A, Hide M. Sweat allergy［J］. Allergol Int, 2018,67（4）:435⁃441. doi: 10.1016/j.alit.2018.07.002.
［20］	Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria［J］. J Am Acad Dermatol, 2000,42（6）:1030⁃1032. doi: 10.1016/s0190⁃9622（00）90299⁃8.
［21］	Gaebelein⁃Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: clinic, diagnostic, course and therapy management in 27 patients［J］. J Dtsch Dermatol Ges, 2020,18（11）:1261⁃1268. doi: 10. 1111/ddg.14309.
［22］	Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine⁃resistant symptomatic dermographism: a pilot study［J］. J Am Acad Dermatol, 2008,59（5）:752⁃757. doi: 10.1016/j.jaad.2008. 07.016.
［23］	Siiskonen H, Smorodchenko A, Krause K, et al. Ultraviolet radiation and skin mast cells: effects, mechanisms and relevance for skin diseases［J］. Exp Dermatol, 2018,27（1）:3⁃8. doi: 10. 1111/exd.13402.
［24］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［25］	宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗27例人工荨麻疹回顾分析［J］. 中华皮肤科杂志, 2021,54（12）:1092⁃1096. doi: 10.35541/cjd.20210473.
［26］	Boyce JA. Successful treatment of cold⁃induced urticaria/anaphylaxis with anti⁃IgE［J］. J Allergy Clin Immunol, 2006,117（6）:1415⁃1418. doi: 10.1016/j.jaci.2006.04.003.
［27］	Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence［J］. J Allergy Clin Immunol, 2018,141（2）:638⁃649. doi: 10.1016/j.jaci.2017.06.032.
［28］	Pressler A, Grosber M, Halle M, et al. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio⁃oedema［J］. Clin Exp Dermatol, 2013,38（2）:151⁃153. doi: 10. 1111/j.1365⁃2230.2012.04430.x.
［29］	Can PK, Salman A, Hoşgören⁃Tekin S, et al. Effectiveness of omalizumab in patients with chronic inducible urticaria: real⁃life experience from two UCARE centres［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:e679⁃e682. doi: 10.1111/jdv.17385.
［30］	Fialek M, Dezoteux F, Le Moing A, et al. Omalizumab in chronic inducible urticaria: a retrospective, real⁃life study［J］. Ann Dermatol Venereol, 2021:S0151⁃9638（21）00063⁃6. doi: 10. 1016/j.annder.2021.04.010.
［31］	Bodar EJ, Simon A, de Visser M, et al. Complete remission of severe idiopathic cold urticaria on interleukin⁃1 receptor antagonist （anakinra）［J］. Neth J Med, 2009,67（9）:302⁃305.
［32］	Gualdi G, Monari P, Rossi MT, et al. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis［J］. Br J Dermatol, 2012,166（6）:1373⁃1374. doi: 10. 1111/j.1365⁃2133.2011.10797.x.
［33］	Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti⁃TNF⁃alpha［J］. J Allergy Clin Immunol, 2007,119（3）:752⁃754. doi: 10.1016/j.jaci.2006. 12.658.
［34］	Ferrucci S, Benzecry V, Berti E, et al. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment［J］. Clin Exp Dermatol, 2020,45（3）:345⁃346. doi: 10.1111/ced.14081.
［35］	Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:e112⁃e113. doi: 10.1111/jdv.14594.
［36］	Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism［J］. J Eur Acad Dermatol Venereol, 2019,33（11）:e413⁃e415. doi: 10.1111/jdv.15720.
［37］	Dickson MC, Walker A, Grattan C, et al. Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a/b randomised double⁃blind placebo⁃controlled study［J］. Br J Clin Pharmacol, 2021 ［2021⁃09⁃01］. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp. 14923. doi: 10.1111/bcp.14923.

[1]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767.
[2]	Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275.
[3]	Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212.
[4]	Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.
[5]	Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644.
[6]	Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694.
[7]	Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184.
[8]	Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156.
[9]	Jiao Xiaoyan, Yin Guangwen, Yin Yakun, Li Dongqin. Clinical analysis of 25 cases of herpes zoster during pregnancy or the perinatal period [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210384-e20210384.
[10]	Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631.
[11]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420.
[12]	Luan Chao, Hu Yu, Chen Kun, Zhang Jiaan, Gu Heng, Zhang Ronglin, Zhang Xiaohua, Tian Panpan, Zhu Yan, Zhuang Chen, Huang Dan, Ju Mei. Efficacy and safety of 308-nm SQ light-emitting diode light and 308-nm excimer light in the treatment of facial vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(1): 16-19.
[13]	Chinese Society of Dermatology, China Dermatologist Association. Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases （2022） [J]. Chinese Journal of Dermatology, 2022, 55(1): 1-11.
[14]	Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64.
[15]	Cao Meng, Hong Anlan, Wang Yan, Fang Fang. Clinical progress in pediatric melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210158-e20210158.

Treatment of chronic inducible urticaria

PDF

Knowledge

Abstract

Cite this article

share this article

References ［37］

Related Articles 15

Metrics

Comments

Recommended 10